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the NetherlandsBackground Dedicated data on the prevalence of incidental findings (IF) stratified according to overall clinical
relevance and their subsequent correlation to outcome are lacking. The aim of the present study was to describe the prevalence
and consequences of noncardiac IF on computed tomography or magnetic resonance imaging in the workup for interventional
cardiovascular procedures.
Methods A total of 916 patients underwent preprocedural computed tomography or magnetic resonance imaging in the
workup for transcatheter aortic valve implantation (TAVI), renal sympathetic denervation (RDN), or MitraClip implantation.
Results IF were found in 395 of 916 patients (43.1%), with an average of 1.8 IF per patient. Classifying the IF resulted in
155 patients with minor, 171 patients with moderate, and 69 patients with major IF. The intended procedure was delayed or
canceled in only 15 of 916 (1.6%) of the patients because of the presence of potential malignant IF. In patients that did
undergo the intended procedure (n = 774), the presence of a moderate or major IF (23.8%) did not impact 1-year mortality
compared to no or minor IF (adjusted HR 0.90, 95% CI 0.56-1.44, P value = .65). These findings were consistent among
patients referred for TAVI, RDN, or MitraClip.
Conclusions IF are frequent in patients referred for cardiovascular procedures. IF did not result in a delay or cancellation
of the intended procedure in the vast majority of cases, irrespective of their clinical relevance. The presence of a major or
moderate IF did not significantly impact 1-year mortality. (Am Heart J 2018;204:83-91.)The number of incidental findings (IF) detected by
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husing high-resolution computed tomography (CT) or
magnetic resonance imaging (MRI) is of paramount
importance to guarantee optimal treatment results.1,2
Although IF have been reported in 25% to 85% of patients
referred for cardiovascular interventions, their clinical
implications most often remain elusive.3-6 Thereby, the
definition of (clinically relevant) IF remains a topic of
debate, explaining the large heterogeneity in reported
prevalences.7,8
At present, dedicated data on the prevalence of IF
stratified according to overall clinical relevance and their
subsequent correlation to outcome are lacking. The aim
of the present study is to describe the prevalence and
consequences of noncardiac IF on CT or MRI in the
workup for transcatheter aortic valve implantation
(TAVI), renal sympathetic denervation (RDN), or Mitra-
Clip implantation.
Figure 1
Total patients referred for TAVI, RDN, and MitraClip implantation.
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Study population
Between May 2009 and December 2016, a total of 1,194
patients were referred for TAVI (n = 1,060), RDN (n =
110), or MitraClip (n = 24) implantation. A total of 278
patients were excluded because of either mortality in the
screening process before radiological evaluation or a
clinical decision not to proceed with screening for the
respective procedure. Eventually, 916 patients with
preprocedural workup including CT (n = 869) or MRI
(n = 47) were included in the final analyses, of which
85.4% were screened for TAVI, 12.0% were screened for
RDN, and 2.6% were screened for MitraClip implantation.
Following the completion of the diagnostic workup and
in accordance with European Society of Cardiology
guidelines,9 all patients referred for TAVI and MitraClip
implantation were discussed in a multidisciplinary team
including interventional cardiologists, cardiothoracic
surgeons, anesthesiologists, and geriatricians. Patients
undergoing RDN in the context of treatment-resistant
hypertension, atrial fibrillation, and heart failure with
reduced ejection fraction were screened according to
recent recommendations.10 A total of 142 patients did not
undergo the procedure for which they were initially
referred (Figure 1).
For the purpose of this study, patients were not subject
to study interventions; neither was any mode of behaviorimposed, other than as part of their regular treatment.
Therefore, according to Dutch law, written informed
consent for a patient to be enrolled in this study was not
required. This study was conducted according to the
privacy policy of the Erasmus MC and to the Erasmus MC
regulations for the appropriate use of data in patient-
orientated research, which are based on international
regulations, including the Declaration of Helsinki. All
patients consented to the use of their data for scientific
research.
The authors are solely responsible for the design and
conduct of this study, all study analyses, the drafting and
editing of the paper, and its final contents.
Definition and methodology
IF were defined as any radiological abnormality not
related to the illness or causes that prompted the
diagnostic imaging test. IF were stratified according to
clinical importance as being either minor (eg, cysts or
osteoarthritis), moderate (eg, pulmonary nodules or
adrenal adenomas), or major (eg, aneurysms, lymphade-
nopathy according to a recently proposed classification
described by Lumbreras et al8). In case multiple IF were
found, the patient was categorized in highest-ranked
cohort (major N moderate N minor) for further analysis.
The impact of the presence of moderate or major IF on
outcome 1-year mortality was based on the cohort of 789
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were deferred because of the presence of IF, excluding
the 127 patients that did not undergo the intended
procedure because of non–IF-related issues (frailty,
vascular access site issues, etc).
Data extraction and follow-up
Data on IF were acquired by evaluating radiologic
findings from preprocedural CT or MRI by specialized
(cardiovascular) radiologists.
Patients were evaluated with CT prior to TAVI to
achieve appropriate valve sizing and to evaluate the best
access pathway before the procedure. The scan protocol
was made up of 3 scans on a second- or third-generation
dual-source CT scanner (Siemens Healthineers, For-
chheim, Germany) for the analysis of the peripheral
access (from the extracranial carotids up to the femoral
bifurcation) and aortic valve assessment. The valve sizing
scan was reconstructed at 0.75-mm slice thickness and
0.4-mm increment at every 5% of the RR interval of the
available data. Peripheral artery access was analyzed on 1-
mm slices with 0.5-mm increment data.
Patients were evaluated with CT prior to MitraClip when
echocardiographic findings were in question; a diagnostic
CT angiography scan was performed of the aorta, heart,
and proximal peripheral access vessels on a dual-source CT
scanner (SiemensHealthineers, Forchheim,Germany). The
scan was performed in dual-source flash mode to obtain
maximum temporal resolution and thereby minimize
motion artifacts of the heart. Scan timing was set to
8 seconds after contrast arrival in the ascending aorta and
the systolic phase of the RR interval. Evaluation was
performed ondatawhichwere reconstructed at≤0.75-mm
slices with 30%-50% slice overlap.
Preprocedural imaging for RDN includes an abdominal
(including arterial phase) CT or MR to confirm anatomical
suitability and as a part of an evaluation for secondary
causes of hypertension. The MR scan protocol prior RDN
was performed on a 1.5-T scanner (Discovery MR450; GE
Medical systems, Milwaukee, WI). A 3D vascular fast time
of flight (TOF) spoiled gradient echo sequencewas used to
acquire images of the renal vasculature. To determine the
arterial scan delay for the contrast-enhanced MR angiogra-
phy (CEMRA) scan, a test bolus sequence was acquired.
Images were acquired during a 20-second breath hold,
depending on the number of slices per slab. An MR
compatible contrast injector (Medrad Spectris,
Warrendale, PA) was used to inject gadobutrol (Gadovist
1.0 mmol/mL; Bayer, Mijdrecht, the Netherlands).
In case of an abdominal CT for RDN, a standard diagnostic
abdominal CT angiography was performed on a multislice
CT scanner ofminimal 128 slices (SomatomAS+, Edge,Drive
or Force; Siemens Healthineers, Forchheim, Germany). The
scan covered the diaphragm trough lesser trochanters.
Evaluation was performed on data which were reconstruct-
ed at ≤0.6-mm slices with 30%-50% slice overlap.Baseline characteristics of all patients were obtained
from local procedural databases and additional medical
record review in case of missing data. Survival informa-
tion was obtained through medical record review and
contact with the municipal civil registries. Median follow-
up period postprocedure was 424 days (131-830).
Funding
No extramural funding was used to support this work.
Statistical analysis
Continuous variables are presented as mean ± standard
deviation. Categorical variables are expressed as percent-
ages. Continuous variables were compared using Student
t test or 1-way analysis of variance in patients with versus
without IF. Comparisons among the 3 groups (major,
moderate, minor) were performed by the F test from an
analysis of variance for continuous variables and
Pearson χ2 test for categorical variables. All statistical
tests are 2-tailed. The incidence of mortality over time
was studied with the use of the Kaplan-Meier method,
whereas log-rank tests were applied to evaluate differences
between the groups. Patients lost to follow-up were
considered at risk until the date of last contact, at which
point they were censored. Cox proportional-hazards
regression analyses were applied to adjust for potential
confounders. Baseline variables with P b .10 in univariate
analyses were entered in a multivariable Cox proportional-
hazards models. Final results are presented as adjusted
hazard ratios with 95% CI. Variables with P b .05 were
considered as statistically significant. Statistical analyses
were performed using SPSS (version 21.0).
Results
Prevalence and types of IF
Mean age of the total population was 78 ± 10 years,
53.8% of the patients were male, and 18.4% had a history
of neoplasms. IF were found in 395 of the 916 patients
(43.1%). No relevant differences were observed in the
baseline characteristics of patients with versus without IF
on preprocedural imaging (Table I).
The total number of IF was 698, resulting in an average
of 1.8 IF per patient with IF in the overall cohort. The
number of IF per patient varied from 1.8 (range 1-5) in the
TAVI cohort to 1.4 IF per patient in the RDN (range 1-3)
and to 1.3 IF per patient in the MitraClip (range 1-2)
cohort, respectively.
The 3 most frequent IF were renal cysts, pulmonary
nodules, and pulmonary consolidations in 16.3%, 13.3%,
and 6.6% of the patients with IF, respectively (Table II).
Classifying the IF resulted in 155 patients (16.9%) with
minor findings, 171 (18.7%) with moderate findings, and
69 patients (7.5%) with major IF. No significant differ-
ences in baseline characteristics were found between
patients identified with either class of IF (Supplement,
Table I. Baseline characteristics of the total study population
All patients Patients with IF Patients without IF P value
N = 916 n = 395 n = 521 (with vs without)
Age, y 78 ± 10 78 ± 10 77 ± 11 .13
Male, n (%) 493 (53.8) 216 (54.7) 277 (53.2) .65
BMI, kg/m2 27.4 ± 8.1 27.6 ± 10.8 27.2 ± 5.2 .53
CV risk factors, n (%)
Diabetes 268 (29.3) 118 (29.9) 150 (28.8) .92
Hypertension 701 (76.5) 290 (73.4) 411 (78.9) .13
Dyslipidemia 553 (60.4) 232 (58.7) 321 (61.6) .64
Smoker, current 73 (8.0) 27 (6.8) 46 (8.8) .04
Prior MI, n (%) 209 (22.8) 82 (20.8) 127 (24.4) .17
Prior PCI, n (%) 304 (33.2) 115 (29.1) 189 (36.3) .04
Prior CVA, n (%) 93 (10.2) 42 (10.6) 51 (9.8) .24
eGFR, mL/min 52 ± 26 52 ± 28 52 ± 25 .99
COPD 192 (21.0) 80 (20.3) 112 (21.5) .23
Neoplasm in history, n (%) 168 (18.4) 76 (19.3) 92 (17.7) .61
Breast cancer 29 (3.2) 12 (3.0) 17 (3.3)
Colorectal cancer 25 (2.7) 12 (3.0) 13 (2.5)
Prostate cancer 23 (2.5) 11 (2.8) 12 (2.3)
Skin cancer 20 (2.2) 10 (2.5) 10 (1.9)
Non-Hodgkin lymphoma 12 (1.3) 6 (1.5) 6 (1.2)
Hodgkin lymphoma 8 (0.9) 6 (1.5) 11 (2.1)
Bladder cancer 11 (1.2) – 6 (1.2)
Lung cancer 10 (1.1) 4 (1.0) 4 (0.8)
Gynecological cancer 8 (0.9) 4 (1.0) 2 (0.4)
Laryngeal cancer 5 (0.5) 2 (0.5) 3 (0.6)
Leukemia 4 (0.4) 3 (0.8) 1 (0.2)
Neuroendocrine cancer 4 (0.4) 1 (0.3) 3 (0.6)
Multiple myeloma 3 (0.3) 2 (0.5) 1 (0.2)
Esophageal cancer 2 (0.2) 2 (0.5) –
RCC 2 (0.2) 2 (0.5) –
Vestibular Schwannoma 2 (0.2) – 2 (0.4)
Values are mean ± SD or n (%). BMI, body mass index; CV, cardiovascular; MI, myocardial infarction; PCI, percutaneous coronary intervention; CVA, cerebrovascular accident;
eGFR, estimated glomerular filtration rate; RCC, renal cell carcinoma.
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476, resulting in an average of 2.0 IF per patient with
moderate or major IF (range 1-5). The number of
moderate or major IF per patient varied from 2.0 (range
1-5) in the TAVI cohort to 1.7 IF per patient in the RDN
(range 1-3) and to 1.3 IF per patient in the MitraClip
(range 1-2) cohort, respectively.
In the 395 patients with IF, active malignancies were
found in 15 cases (3.8%). Malignancies included lung
carcinoma (n = 8), breast cancer (n = 3), bladder cancer
(n = 1), renal carcinoma (n = 1), non-Hodgkin lymphoma
(n = 1), and multiple myeloma (n = 1). In patients with a
history of neoplasms (n = 168), IF were present in 76 cases
(45%) and proved to be malignant in 7 cases (4.2%).
Consequences
A total of 142 patients of the initially screened cohort of
916 patients eventually did not undergo the procedure
for which they were initially referred (Figure 1).
Procedures were delayed (n = 7) or canceled (n = 8) in
15 of 916 cases (1.6%) because of the presence of IF(breast cancer, lymphoma, renal cell carcinoma, lung
cancer, bladder cancer). Mean delay was 130 ± 120 days.
Procedures did not take place in the remaining cases
because of either a variety of non–IF-related issues
(comorbidity, vascular access issues, renal anatomy not
compatible for current intravascular treatment options
for RDN, nonsevere valvular heart disease) or death while
waiting for the intended procedure.
Impact on mortality
Unadjusted cumulative 1-year mortality was compara-
ble in patients (n = 789) with versus those without IF
(14.9% vs 16.1%; log-rank P = .82). Unadjusted cumula-
tive 1-year mortality rates were 14.8% in patients with no
or minor IF and 18.5% in patients with moderate or major
IF (P = .25).
In patients that eventually underwent the procedure
(n = 774), 1-year mortality rates were identical in patients
with versus without moderate or major IF (14.3% vs.
14.8%, respectively; log-rank P = .87; adjusted HR 0.90;
95% CI 0.56-1.44; P = .65) (Figure 2). Renal insufficiency
Table II. Specification of IF per category (n = 698)
Organ system Major (90) Moderate (287) Minor (321)
Head-chest Laryngeal mass (2) Thyroid IF (39)
Vascular Aortic aneurysm (22) Abdominal aortic ectasia (2)
Hepatic hemangioma (16)
Renal artery stenosis (31)
FMD (3)
MVD (24)
Carotid disease (29)
Reticuloendothelial Lymphadenopathy (43) Splenomegaly (1) Splenic cyst (2)
Thoracic cavity Pulmonary mass (7)
Pulmonary embolism (2)
Pulmonary nodules (93)
Pulmonary consolidation (46)
Pleural plaques (32)
Hepatobiliary Pancreatitis (2)
Pancreatic calcification (1)
Liver cirrhosis (2)
Cholelithiasis (26)
Pancreatic cyst (6)
Hepatic steatosis (7)
Liver cyst (40)
Peritoneal cavity Renal mass (9)
Pelvic mass (3)
Adrenal adenoma (15)
Adrenal mass (benign) (23)
Renal cyst (114)
Adrenal cyst (1)
Gastrointestinal tract Diverticulosis (44)
Gynecological Breast mass (2) Uterine enlargement (3) Ovarian cyst (4)
Breast cyst (2)
FMD, fibromuscular disease; MVD, mesenteric vascular disease.
Figure 2
Cumulative 1-year mortality in patients that underwent the intended procedure (n = 774) stratified according to the presence of a moderate or major IF.
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baseline appeared to be the sole independent predictors of
1-year mortality (Table III). Finally, also the total number of
moderate or major IF was not a predictor for 1-year
mortality (adjusted HR 0.91; 95% CI 0.73-1.14; P = .41).
In the cohort of patients that did not undergo the intended
procedure (n = 142), 1-year mortality rates were numerical-
ly higher in the cohort with moderate or major IF (57.9%)versus the cohort with no or minor IF (31.1%) (adjusted HR
1.51; 95% CI 0.81-2.82; P = .20) (Figure 3). Renal insuffi-
ciency appeared to be the sole independent predictor of 1-
year mortality (Table IV). Also in this cohort, the total
number of moderate or major IF was not a predictor for 1-
year mortality (adjusted HR 1.14; 95% CI 0.89-1.46; P = .29).
In patients in whom the intended procedure
was delayed or canceled because of the presence of IF
Table III. Multivariate predictors of 1-year mortality in patients
who underwent the intended procedure (n = 774)
Variable
Unadjusted HR Adjusted HR
HR (95% CI; P value) HR (95% CI; P value)
Age 1.00 (0.98-1.02; .93)
Female sex 0.89 (0.60-1.33; .57)
Hypertension 0.72 (0.46-1.13; .15)
Diabetes mellitus 1.28 (0.85-1.93; .24)
Dyslipidemia 0.68 (0.46-1.00; .05) 0.69 (0.46-1.02; .06)
Smoking 1.00 (1.00-1.01; .30)
Prior PCI 0.85 (0.56-1.30; .45)
Prior MI 1.36 (0.89-2.06; .16)
Prior CVA 1.46 (0.85-2.49; .17)
COPD 1.67 (1.12-2.48; .01) 1.58 (1.06-2.35; .023)
Malignancy in history 0.95 (0.67-1.38; .79)
Renal insufficiency 1.73 (1.06-2.83; .03) 1.65 (1.01-2.70; .046)
Moderate-major IF 0.96 (0.60-1.54; .87) 0.90 (0.56-1.44; .65)
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because of a malignancy underlying their IF, whereas 4
patients died because of their initial cardiac condition
while waiting for additional analyses of the IF.
Sensitivity analyses in the cohort of patients that under-
went TAVI revealed similar findings, with an adjusted 1-year
mortality rate for the presence of moderate or major IF of
1.37 (95% CI 0.96-1.96;P = .09). Renal insufficiencywas the
only independent predictor of 1-year mortality (adjusted HR
1.76, 95% CI 1.12-2.81; P = .02) (Supplement, Table SII). A
subanalysis in the cohort of patients that underwent RDN or
MitraClip showed also that the presence of a moderate or
major IFwas not a predictor for 1-yearmortality (adjustedHR
0.98; 95% CI 0.11-8.13; P = .98).
Additionally, the total number of moderate or major IF
did not impact 1-year mortality in patients that underwent
TAVI (adjusted HR 1.04; 95% CI 0.81-1.34; P = .75).Discussion
In this large-scale retrospective single-center registry,
we demonstrate that IF are frequently detected in
patients screened for TAVI, RDN, or MitraClip implanta-
tion. In 43.1% of the patients referred, noncardiac IF were
found. Although the majority of the total number of IF
were minor, the presence of moderate or major IF
resulted in a delay or cancellation of the intended
procedure in only a fraction of the patients and did not
significantly impact 1-year mortality.
Preprocedural screening can identify an asymptomatic
disease, a risk factor, or a harmful disease such as a
malignancy.4,11,12 The present study demonstrates that a
broad spectrum of IF can be found in patients referred for
percutaneous cardiovascular interventions. Of the 698 IF
found in a total of 395 patients with IF, 39.2% of the
patients were diagnosed only with a finding of minor
clinical relevance, mostly determined by the presence ofrenal cysts (114/698). Although this is in line with
previous studies showing that most of the IF are believed
to be benign, it could explain the lack of a correlation
between the presence of an IF per se and outcome in
previous studies.2,7,11,13,14
To the best of our knowledge, the present study is the
first to assess whether IF stratified according to clinical
relevance could predict 1-year mortality. To stratify the
IF, we used a classification into 3 categories: minor,
moderate, or major, as previously described by Lum-
breras et al.8 In their systematic review comprising 44
studies, the authors reported a mean IF frequency of
23.6%. Follow-up was initiated in only 64.5%, and with a
lack of specific outcome data in the vast majority of the
cases, the authors concluded that the optimal manage-
ment strategy for these findings remains elusive.
The present study demonstrates that the presence of a
moderate or major IF did not significantly impact 1-year
mortality rates in patients undergoing TAVI, RDN, or
MitraClip implantation. This finding was consistent among
the individual subgroups of TAVI, RDN, or MitraClip.
Instead, renal insufficiency and COPD at baseline appeared
to be the sole independent predictors for 1-year mortality.
Previous work by Orme et al concluded that a higher
number of potentially pathological IF per patient might
impact 2-year mortality in 424 patients screened for TAVI.15
In the subgroup of patients from our study that were
screened for TAVI (n = 782), we were not able to confirm
that the number of moderate or major IF per patient
significantly predicts 1-year mortality. This discrepancy
might be explained by the exceptionally high number of
IF detected in the work by Orme et al. The authors reported
an average of at least 5.3 IF per patient as compared to 1.8 in
the present study, 0.3 in a large registry by Koonce et al, and
0.4 in previous work specifically focusing on TAVI
patients.2,6
Untreated symptomatic severe aortic stenosis has been
associated with 1-year mortality rates of up to 50%.16 In
patients that actually underwent the intended procedure
in the present study, survival curves in patients with
moderate or major IF as compared to those with minor or
no IF were superimposed.
Additional analyses in patients that did not undergo the
intended procedure revealed an increased crude mortal-
ity rate when moderate of major IF were present. The
mortality difference in this subset appeared to be
explained by the fact that 14 of 15 patients with moderate
or major IF died, 10 because of the consequences of the
IF; however, 4 patients died because of their underlying
cardiac condition for which the treatment was delayed
for IF screening purposes. Although the latter is in
agreement with recent guidelines for valvular heart
disease in which TAVI is only indicated in patients with
a life expectancy of at least 1 year, it also illustrates that
delaying a potentially lifesaving cardiovascular interven-
tion could have important clinical implications.9
Table IV. Multivariate predictors of 1-year mortality in patients
who did not undergo the intended procedure (n = 142)
Variable
Unadjusted HR Adjusted HR
HR (95% CI; P value) HR (95% CI; P value)
Age 1.05 (1.02-1.08; b.01) 1.02 (0.98-1.06; .29)
Female sex 1.35 (0.74-2.46; .33)
Hypertension 0.86 (0.46-1.61; .64)
Diabetes mellitus 1.65 (0.91-3.02; .10)
Dyslipidemia 1.63 (0.88-3.02; .10)
Smoking 1.01 (1.00-1.01; .08) 1.00 (1.00-1.01; .23)
Prior PCI 0.98 (0.52-1.84; .94)
Prior MI 0.81 (0.44-1.51; .51)
Prior CVA 1.40 (0.52-3.76; .51)
COPD 0.85 (0.38-1.89; .68)
Malignancy in history 1.00 (0.94-1.07; .98)
Renal insufficiency 5.40 (1.93-15.1; b.01) 3.62 (1.16-11.3; .03)
Moderate-major IF 2.02 (1.11-3.70; .02) 1.51 (0.81-2.82; .20)
Figure 3
Cumulative 1-year mortality in patients that did not undergo the intended procedure (n = 142) stratified according to the presence of a moderate
or major IF.
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intended procedures were delayed or canceled in only a
fraction of the patients (15/916) because of the presence
of active malignancies deserving further attention in a
study cohort in which the average age was 78 years.
Although these numbers might appear trivial, a total of
698 IF were found in the present study comprising 916
patients. Unfortunately, we do not have specific detailson the screening process of patients referred for
additional diagnosis. Nevertheless, it is likely that the
presence of IF might have caused a significant clinical and
economic burden to both patient and health care parties.
Currently, there is a broad variety in the quality of
international guidelines for follow-up of specific IF. Some
are clear from a radiological perspective, whereas others
need extensive clinical data which are usual not readily
available to radiologist or even local operator. The latter
leads to extensive heterogeneity in how these recom-
mendations are being followed up in clinical practice. Lee
et al described that only in one-third of the patients in
which IF were found did radiologists recommend further
follow-up.17 In the vast majority of radiology reports in
patients with IF, explicit follow-up recommendations are
lacking. On the other hand, the same study reports that,
frequently, in case follow-up recommendations were
explicitly reported, clinical and imaging follow-up was
not performed. Although precise reporting by radiolo-
gists is essential, we should realize that previous imaging
data from patients referred for TAVI, RDN, or MitraClip in
tertiary referral centers are usually not readily available,
complicating validated follow-up recommendations. Fi-
nally, radiologists are frequently not part of multidisci-
plinary teams involved in decision making regarding high-
risk cardiovascular procedures.18
Finally, the total number of IF will only increase along
with the improving image quality of current-generation
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malignancies, there seems currently no reason to delay or
cancel potential lifesaving procedures as TAVI based on
the presence of IF. Furthermore, with a prevalence of
43.1% of non–clinically evident radiological findings,
there is need for larger prospective studies focusing on
the sense and nonsense of follow-up of a broad spectrum
of these findings, allowing the development of practical
guidelines helping physicians in deciding whether or not
to refer a patient for additional screening. Until then, it
remains important that, in case of IF, a follow-up plan
should be made along with a decision as to whether or
not the intended procedure should be delayed. Based on
the data presented above, the presence of a moderate or
major IF did not impact 1-year mortality.
Limitations
The present study has several limitations. First, detailed
data on the percentage of patients with IF that did
undergo additional tests are unknown, precluding any
statements on their potential clinical and economic
consequences. This limitation was inherent to the nature
of our institution, being a tertiary referral site for the
previously mentioned procedures. Dedicated follow-up
for IF was left to the discretion of the referring physician.
Second, we might have underestimated the actual
incidence of IF because of a lack of structural reporting
and the use of different scan protocols associated with
the different imaging modalities used. Third, the classi-
fication of IF in 3 categories remains disputable and has
not been considered a strict rule to stratify these
abnormalities. Moderate IF such as adrenal adenomas or
breast nodules might become major clinical problems in
cases associated with an active malignancy. In the present
study, however, the prevalence of active malignancies
was only 1.6%, suggesting that, in the vast majority of
cases, IF were benign. Besides these known limitations,
we were the first to assess whether classification of IF
into these 3 categories resulted in different 1-year
mortality rates, potentially justifying a differential screen-
ing approach to those with moderate of major IF.Conclusion
IF are frequent in patients referred for percutaneous
cardiovascular procedures. IF did not result in a delay or
cancellation of the intended procedure in the vast
majority of the cases, irrespective of their severity. The
presence of a major or moderate IF did not significantly
impact 1-year mortality in patients referred for TAVI,
RDN, or MitraClip implantation.
Impact on daily practice
The total number of IF detected on current generation
CT or MRI scanners will increase because of improving
image quality. The strongest predictor for prognosis inpatients as described in this study remains whether or not
they undergo the procedure for which they are initially
referred. There is need for larger prospective studies
focusing on the sense and nonsense of follow-up of a broad
spectrum of these findings, allowing the development of
practical guidelines helping physicians in deciding whether
or not to refer a patient for additional screening.
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